A study looking at a drug called ADP-A2AFP (AFPc332T) for liver cancer
Cancer type:
Status:
Phase:
This study looked at how safe a drug called ADP-A2AFP was for liver cancer. It also looked at how well it worked.
It was for people who had a cancer that started in the liver. This is called a
of the liver. Everyone taking part had already had treatment but their cancer got worse.
The study was open for people to join between 2017 and 2021. The team reported the results in 2024.
More about this trial
In this study, researchers looked at using changed . These T cells were from your own body. T cells are a part of your . They help fight diseases including cancer.
The study team took some T cells from the blood of the people in the trial. They then changed them in the lab. They changed the of the T cells. This meant that they better recognised and fought cancer. The changed T cells were called ADP-A2AFP.
The people taking part had chemotherapy. Then 4 or 5 days later they had ADP-A2AFP. They had this as a drip into a vein or through a central line. The ADP-A2AFP each person had was made from their own T cells only.
The main aims of this study were to find out:
- how safe it is to have ADP-A2AFP
- how well people tolerate having it
- how well it works
- what the side effects are
Summary of results
Of the 477 people the team screened, 38 had their T cells collected. Of these 38 people, 21 had ADP-A2AFP.
The team looked at how well ADP-A2AFP worked. They found that for:
- 1 person there was no sign of their cancer
- 1 person their cancer had shrunk
- 12 people their cancer had stayed the same
- 7 people their cancer got worse
Two people had a second treatment with ADP-A2AFP and their cancer had stayed the same.
Side effects
All 21 people had a side effect. The most common side effect was a drop in blood cells that could cause:
- an increased risk of infection
- bruising and bleeding
- breathlessness
- tiredness
Conclusion
The team concluded that the side effects of ADP-A2AFP are acceptable.
When we wrote this summary the team are still following up 1 person who took part in the study.
Where this information comes from
We have based this summary on information from the research team. As far as we are aware, the information they sent us has not been reviewed independently () or published in a medical journal yet. The figures we quote above were provided by the research team. We have not analysed the data ourselves.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Tim Myer
Supported by
Adaptimmune LLC
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
